Novo Nordisk CEO tells investors to expect weight-loss drug pricing to go down before it comes back up

Core Viewpoint - Novo Nordisk's CEO Mike Doustdar provided a pessimistic outlook on the company's prospects for 2026 during a media briefing following the pre-announcement of earnings [1] Group 1 - The company pre-announced its earnings a day prior to the media engagement [1] - CEO Mike Doustdar expressed concerns regarding the company's future performance [1]